|Systematic (IUPAC) name|
|Bioavailability||almost complete (~80%)|
|Biological half-life||~0.8 hours|
|ATC code||C03CA02 (WHO)|
|Molar mass||364.417 g/mol[[Script error: No such module "String".]]|
|Script error: No such module "collapsible list".|
Bumetanide (Trade name Bumex) is a loop diuretic of the sulfamyl category to treat heart failure. It is often used in patients in whom high doses of furosemide are ineffective. It is marketed by Hoffmann-La Roche with the brand name Bumex. The main difference between the two substances is in bioavailability and pharmacodynamic potency. Furosemide is incompletely absorbed in the intestine (60%), and there is substantial inter- and intraindividual differences in bioavailability (range 10-90%). Bumetanide is completely absorbed (80%), and the absorption is not altered when it is taken with food. It is said to be a more predictable diuretic, meaning that the predictable absorption is reflected in a more predictable effect.
On October 24, 2008, ESPN reported a number of NFL players were being suspended under the steroid policy as a result of taking Bumetanide. The drug is often used for weight loss, but also to mask other drugs or steroids by helping to dilute the contents of the user's urine (which is manifested through its actions on the Loop of Henle -- see loop diuretic), yielding a lower concentration of filtered substances which may then go undetected.
Bumetanide was an undisclosed active ingredient in the over the counter weight loss supplement StarCaps. StarCaps was pulled off the market after the presence of the undisclosed ingredient was discovered by the Food and Drug Administration.
Cite error: Invalid
parameter "group" is allowed only.
<references />, or
<references group="..." />
|30px||This drug article relating to the cardiovascular system is a stub. You can help ssf by expanding it.|
- Brunton, Laurence et al. Goodman & Gilman's The Pharmacological Basis of THERAPEUTICS. 11th ed. 2006. 749-753